<h4>Background</h4>The detection of estrogen receptor 1 (<i>ESR1</i>) ligand-binding domain mutations in circulating tumor DNA (ctDNA) is crucial for guiding therapy in estrogen receptor-positive metastatic breast cancer. Here, ESR1 is linked to neoplasm.